Meeting
2015 ASCO Annual Meeting
Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.
Authors
Tanya B. Dorff
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Tanya B. Dorff , Jeff Longmate , Sumanta Kumar Pal , Walter Michael Stadler , Mayer N. Fishman , Ulka N. Vaishampayan , Amol Rajeev Rao , James Hu , David I. Quinn , Primo Lara Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01727089
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4542)
DOI
10.1200/jco.2015.33.15_suppl.4542
Abstract #
4542
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).
First Author: Tanya B. Dorff
Poster
2015 Genitourinary Cancers Symposium
A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.
First Author: Toni K. Choueiri
Poster
2017 ASCO Annual Meeting
Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.
First Author: Yingmiao Liu
Poster
2014 ASCO Annual Meeting
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.
First Author: Vicky Makker